Overview

Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery

Status:
Completed
Trial end date:
2019-02-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, toxicity and feasibility of FOLFOX/ bevacizumab and FOLFOXIRI/ bevacizumab neoadjuvant therapy in poor prognosis rectal cancer as defined by MRI.
Phase:
Phase 2
Details
Lead Sponsor:
University College, London
Collaborators:
Cancer Research UK
Hoffmann-La Roche
Treatments:
Bevacizumab
Fluorouracil
Irinotecan
Oxaliplatin